New treatments for chronic obstructive pulmonary disease;Enfermedad pulmonar obstructiva crónica

Medicina Clinica

Volumn 125, Issue 2, 2005, Pages 65-74

  Miravitlles, Marc ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Bronchodilators; COPD; Inhaled steroids; Tiotrope; Treatment

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID; IMMUNOMODULATING AGENT; IPRATROPIUM BROMIDE; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROLIPRAM; STEROID; TERBUTALINE; THEOPHYLLINE DERIVATIVE;

ARTICLE; BRONCHUS HYPERREACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; DRUG CHOICE; EXERCISE; FORCED EXPIRATORY VOLUME; GRAVITY; HUMAN; IMMUNOMODULATION; INDIVIDUALIZATION; LUNG FUNCTION; MEDICAL DECISION MAKING; META ANALYSIS; RELAPSE; SPIROMETRY; STEROID THERAPY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 22544438725     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13076464     Document Type: Article

References (91)

1. Sobradillo V, Miravitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, et al. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest. 2000;118:1278-85.
2. Cerveri I, Accordini S, Verlato G, Corsico A, Zaoia MC, Casali L, et al. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J. 2001;18:85-92.
3. Peris Cardells R, Rico Salvador I, Herrera de Pablo P, Pérez Jiménez A, Sánchez-Toril López F, Pérez Fernández JA. Estudio demográfico del tabaquismo en el Área de Salud 5 de Valencia. Arch Bronconeumol. 2004; 40:160-5.
4. Miravitlles M, Murio C, Guerrero T, Gisbert R, on behalf of the DAFNE study group. Costs of chronic bronchitis and COPD. A one year follow-up study. Chest. 2003;123:784-91.
5. Masa JF, Sobradillo V, Villasante C, Jiménez-Ruiz CA, Fernández-Fau L, Viejo JL, et al. Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional. Arch Bronconeumol. 2004;40:72-9.
6. Miravitlles M, Figueras M. El coste de la enfermedad pulmonar obstructiva crónica en España. Opciones para una optimización de recursos. Arch Bronconeumol. 2001;37:388-93.
7. Miravitlles M, Fernández I, Guerrero T, Murio C. Desarrollo y resultados de un programa de cribado de la EPOC en Atención Primaria. El proyecto PADOC. Arch Bronconeumol. 2000;36:500-5.
8. Office of the Surgeon General. Tobacco Cessation Guideline. Disponible en: www.surgeongeneral.gov/tobacco/default.htm
9. Álvarez-Sala JL, Cimas E, Masa JF, Miravitlles M, Molina J, Naberan K, et al. Recomendaciones para la atención al paciente con enfermedad pulmonar obstructiva crónica. Arch Bronconeumol. 2001;37:269-78.
10. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004;125:249-59.
11. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997;155:1283-9.
12. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004;24:86-94.
13. Man WDC, Mustfa N, Nikoletou D, Kaul S, Hart N, Rafferty GF, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax. 2004;59:471-6.
14. Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J. 2002;19:936-43.
15. Dahl R, Greefhorts LAPM, Nowak D, Nonikov V, Byrne AM, Thompson MH, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:778-84.
16. Van Noord JA, De Munck DRAJ, Bantje ThA, Hop WCJ, Akveld MLM, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J. 2000;15:878-85.
17. ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 2001;119:1661-70.
18. D'Urzo AD, De Salvo MC, Ramírez-Rivera A, Almeida J, Sichletidis L, Rapatz G, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. Chest. 2001;119:1347-56.
19. Cook D, Guyatt G, Wong E, Goldstein R, Bedard M, Austin P, et al. Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 163:85-90.
20. Dekker FW, Dieleman FE, Kaptein AA, Mulder JD. Compliance with pulmonary medication in general practice. Eur Respir J. 1993;6:886-90.
21. Gross NJ. Tiotropium bromide. Chest. 2004;126:1946-53.
22. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1136-42.
23. Van Noord JA, Bantje TA, Korducki L, Cornelissen PJG, on behalf of the Dutch Tiotropium Study Group. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax. 2000;55:289-94.
24. Van Noord JA, Smeets JJ, Custers FL, Korducki L, Cornelissen PJG. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J. 2002;19:639-44.
25. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124:1743-8.
26. O'Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise ntolerance in COPD. Eur Respir J. 2004;23:832-40.
27. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following six months treatment with once daily tiotropium compared to twice daily salmeterol in patients with COPD. Thorax. 2003;58:399-404.
28. Tsukino M, Nishimura K, Ikeda A, Hajiro T, Koyama H, Izumi T. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonay disease. Thorax. 1998; 53:269-73.
29. Culpitt SV, De Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;165:1371-6.
30. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax. 1998;53:129-36.
31. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet. 2004;363:731-3.
32. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297-303.
33. Pauwels RA, Löfdahl C-G, Laitinen LA, Scheuten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med. 1999;340:1948-53.
34. 1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med. 2003;138:969-73.
35. Sutherland ER, Allmenrs H, Ayas NT, Venn AJ, Martin RJ. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2003;58:937-41.
36. Van Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary diseases meta-analysis. Thorax. 1999;54:7-14.
37. 1 during long-term inhaled conticosteroid treatment. Eur Respir J. 1993;6:868-76.
38. Alsaeedi A, Sin DD, McAlister FA. The effect of inhaled corticosteroids in chronic obstructive pulmonary diseases systematic review of randomized placebo-controlled trials. Am J Med. 2002;113:59-65.
39. Jones PW, Willits LR, Burge PS, Calverley PMA. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 2003;21:68-73.
40. Fabbri LM, Hurd SS, for the GOLD Scientific Committee. Global strategy for the diagnosis, management and prevention of COPD:2003 update. Eur Respir J. 2003;22:1-2.
41. Albers M, Schermer T, Van den Boom G, Akkermans R, Van Schayck C, Van Herwaarden C, et al. Efficacy of inhaled steroids in undiagnosed subjects at risk for COPD. Chest. 2004;126:1815-24.
42. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids. Chest. 2004;126:213-9.
43. Hubbard RB, Smith CJP, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture. A population-based case-control study. Am J Respir Crit Care Med. 2002;166:1563-6.
44. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:1084-91.
45. Donohue JF, Van Noord JA, Bateman ED, Langley SJ, Lee A, Witek Jr. TJ, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122:47-55.
46. Calverley P, Pawels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a rendomised controlled trial. Lancet. 2003;361: 449-56.
47. Szafranski W, Cukier A, Ramírez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74-81.
48. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912-9.
49. Miravitlles M. ¿Se debe revisar el concepto de EPOC y bronquitis cronica? JANO. 2000;58:34-6.
50. Sin DD, McAlister FA, Man SFP, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease. JAMA. 2003;290: 2301-12.
51. Cazzola M, Dahl R. Inhalde combination therapy with long-acting beta2-agonists and corticosteroids in satble COPD. Chest. 2004;126:220-37.
52. Cazzola M, Santus P, Di Marco F, Boveri B, Castagna F, Carlucci P, et al. Bronchodilator effect of an inhlade combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. Respir Med. 2003;97:453-7.
53. Miravitlles M. El fracaso en el tratamiento de las agudizaciones de la enfermedad pulmonar obstructiva crónica. Factures de riesgo e importancia clínica. Med Clin (Barc). 2002;119:304-14.
54. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. 2002;20:819-25.
55. Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J. 2004;23:391-5.
56. The TORCH study group. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J. 2004;24:206-10.
57. Vignola AM. PDE4 inhibitors in COPD - a more selective approach to treatment. Respir Med. 2004;98:495-503.
58. Profita M, Chiappara G, Mirabella F, Di Giorgi R, Chimenti L, Costanzo G, et al. Effect of cilomilast (Ariflo) on TNF-oc, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax. 2003;58:573-9.
59. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet. 2001;358:265-70.
60. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 2001;297;280-90.
61. Rabe KF, Chapman KR, Joubert J, Vetter N, Witte S, Bredenbroeker D. Roflumilast, a novel, selective phosphodiesterase 4 inhibitor, improves lung function in patients with moderate to severe COPD. Am J Respir Crit Care Med. 2004;169:A518.
62. O'Donnell D, Muir JF, Jenkins C, Plit M, Brockhaus F, Witte S, et al. Roflumilast, a novel, selective phosphodiesterase 4 inhibitor, improves quality of life and lowers exacerbation rate in patients with moderate to severe COPD. Am J Respir Crit Care Med. 2004;169:A602.
63. Bateman ED, Holmes M, Muir JF, Andrae K, Witte S, Bredenbroeker D. Safety profile of roflumilast, a novel, selective phosphodiesterase 4 inhibitor, in patients with moderate to severe COPD. Am J Respir Crit Care Med. 2004;169:A596.
64. Zühlke IE, Kanniess F, Richter K, Nielsen-Gode D, Böhme S, Jörres RA, et al. Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD. Eur Respir J. 2003;22:926-30.
65. Gompertz S, Stockley RA. A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest. 2002;122:289-94.
66. Rubinstein I, Kumar B, Schriever C. Long-term montelukast therapy in moderate to severe COPD - a preliminary observation. Respir Med. 2004; 98:134-8.
67. Cazzola M, Centanni S, Boveri B, Di Marco F, Santus P, Matera MG, et al. Comparison of the bronchodilating affect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. Respiration. 2001;68:452-9.
68. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD. Chest. 2004;26:926-34.
69. Miravitlles M, Mayordomo C, Artés M, Sánchez-Agudo L, Nicolau F, Segú JL, on behalf of the EOLO Group. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir Med. 1999;93:173-9.
70. Miravitlles M, Murio C, Guerrero T, Segú JL. Tratamiento de la bronquitis crónica y la EPOC en Atención Primaria. Arch Bronconeumol. 1999;35:173-8.
71. De Miguel J, Izquierdo Alonso JL, Rodriguez González-Moro, De Lucas Ramos P, Molina París J. Tratamiento farmacológico de la EPOC en dos niveles asistenciales. Grado de adecuación a las normativas recomendadas. Arch Bronconeumol. 2003;39:195-202.
72. Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000;16:253-62.
73. Decramen M, Dekhuijzen PNR, Troosters T, Van Herwaarden C, Ruttenvan Mölken M, Van Schayck CPO, et al. The bronchitis randomized on NAC cost-utility study (BRONCUS): hypothesis and design. Eur Respir J. 2001;17:329-36.
74. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: a systematic review. BMJ. 2001;322: 1271-4.
75. Malerba M, Ponticiello A, Radaeli A, Bensi G, Grassi V. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST trial). Pulm Pharmacol Ther. 2004;17:27-34.
76. Steurer-Stey C, Bachmann LM, Steurer J, Tramèr MR. Oral purified bacterial extracts in chronic bronchitis and COPD. Chest. 2004;126:1645-55.
77. Venge P, Pedersen B, Hakansonn L, Hallgren R, Lindblad G, Dahl R. Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis. Am J Respir Crit Care Med. 1996;153:312-6.
78. Baños V, Gómez J, García A, Ruiz J, Álvarez R, Lorenzo M, et al. Effectiveness of immunomodulating treatment (Thymostimulin) in chronic obstructive pulmonary disease. Respiration. 1997;64:220-3.
79. Prieto A, Reyes E, Bernstein ED, Martínez B, Montserrat J, Izquierdo JL, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (Inmunoferon). Am J Respir Crit Care Med. 2001;163:1578-83.
80. Álvarez-Mon M, Miravitlles M, Morera J, Callol L, Álvarez-Sala JL. Treatment with the immunomodulator AM3 (inmunoferon) improves the health-related quality of life of patients with chronic obstructive pulmonary disease. Chest. 2005;127:1205-11.
81. Masaro GD, Masaro D. Retinoid acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med. 1997;3:675-7.
82. Mao JT, Goldin JG, Dermand J, Ibrahim G, Brown MS, Emerick A, et al. A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am J Respir Crit Care Med. 2002;165:718-23.
83. Mahler DA, Donohue JF, Bargee RA, Goldman MD, Gross NJ, Wisniewski ME, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115:957-65.
84. Vincken W, Van Noord JA, Greefhorst APM, Bantje TA, Kesten S, Korducki L, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002;19:209-16.
85. Jones PW, Wilson K, Sondhi S. Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respir Med. 2003;97:20-6.
86. Oostenbrink JB1 Ritten-van-Mölken MPMH, Al MJ, Van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J. 2004;23:241-9.
87. Hogan TJ, Geddes R, González ER. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clin Ther. 2003;25:285-97.
88. Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, Di Marco F, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med. 2004;98:1214-21.
89. Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera MG, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther. 2004;17:35-9.
90. Miravitlles M, Álvarez-Sala JL, Lamarca R, Ferrer M, Masa F, Verea H, et al, for the IMPAC study group. Treatment and quality of life in patients with chronic obstructive pulmonary disease. Qual Life Res. 2002;11:329-38.
91. Miravitlles M. Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur Respir J. 2002;20:243-4.